Key facts
- It has raised $335.9M; the latest was Later Stage VC ($34.5M) in Oct 2025.
- Notable investors include European Innovation Council, GV, SoftBank Investment Advisers, F-Prime Capital, Qiming Venture Partners — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Leyden Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Leyden Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leyden Labs
Developer of a mucosal protection platform designed to provide protection against respiratory viruses like influenza and coronaviruses. The company offers a portfolio of nasal sprays, enabling individuals to reduce the risk of infection, with a focus on improving public health through innovative protection methods.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2020
- Employees
- 78
- Website
- leydenlabs.com/
- Ownership
- Privately Held (backing)
Leyden Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leyden Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leyden Labs in its N-PORT filings yet. We sweep new filings monthly.